11 citations
,
November 2022 in “Journal of Endocrinological Investigation” In this study, gender-affirming hormonal treatment was associated with increased hair growth, acne, and alopecia prevalence in transgender individuals assigned female at birth, while opposite dermatological changes were observed in those assigned male at birth.
1 citations
,
September 2021 in “Frontiers in Endocrinology” This case report describes the use of topical minoxidil to successfully promote facial hair growth in a 17-year-old trans male unable to start testosterone therapy, with skin dryness as the only reported side effect.
12 citations
,
July 2020 in “Dermatologic Therapy” This review discusses the use of topical and oral minoxidil for pediatric hair disorders, pointing out the lack of guidelines and the potential risks associated with systemic absorption, but reports no clinical results.
59 citations
,
July 2020 in “Journal of The American Academy of Dermatology” This study concluded that oral minoxidil is an effective and well-tolerated alternative to topical minoxidil for healthy patients struggling with application-related compliance issues.
19 citations
,
June 2020 in “International Journal of Dermatology” In this systematic review, oral minoxidil was found to be a safe and effective treatment for androgenetic alopecia and alopecia areata, with additional benefits for female pattern hair loss and other types of alopecia, although common side effects included hypertrichosis and postural hypotension.
8 citations
,
April 2020 in “Facial Plastic Surgery Clinics of North America” This abstract explains that androgenetic alopecia, a common hair loss disorder influenced by genetics and hormones like dihydrotestosterone, has FDA-approved treatments including minoxidil, finasteride, and photolaser therapy, but its genetic basis and susceptibility to environmental factors remain complex.
8 citations
,
November 2019 in “Dermatologic Clinics” This study highlights the importance of clinicians understanding the effects of gender-affirming hormones like testosterone, estrogen, and antiandrogens on hair growth, to effectively diagnose and treat androgenetic alopecia in gender minority patients.
71 citations
,
August 2019 in “The journal of sexual medicine” In this study, transgender adolescents treated with testosterone for a median of 12 months experienced effective virilization, including voice deepening and increased hair growth, but also showed decreased HDL cholesterol and BMD z-scores, and increased hematocrit, with no short-term safety issues reported.
36 citations
,
May 2017 in “The journal of sexual medicine” In this retrospective study, cyproterone acetate treatment in late-pubertal trans-girls was found to be generally safe and led to mild feminizing effects, with more rapid feminization occurring when combined with estrogens.
101 citations
,
January 2016 in “Journal of Cutaneous and Aesthetic Surgery” This review discusses various classification systems for patterned hair loss in both sexes and reports no new clinical findings, highlighting the Hamilton-Norwood and Ludwig systems as the most commonly used.
69 citations
,
July 2015 in “Pharmacotherapy” This study found that low-dose finasteride use in young men was associated with higher reporting of persistent sexual dysfunction, with some cases linked to suicidal ideation.
204 citations
,
May 2014 in “The Journal of Sexual Medicine” This study concluded that current cross-sex hormone treatments for trans men and trans women are effective with a low risk of side effects in the short term, though they did observe specific clinical changes.
110 citations
,
October 2013 in “The Journal of Sexual Medicine” This study found that testosterone therapy in trans men increased facial and body hair growth while the prevalence and severity of acne peaked at 6 months but were primarily mild after long-term treatment.
134 citations
,
August 2012 in “The Journal of Clinical Psychiatry” This study found that former finasteride users with persistent sexual side effects reported significantly higher rates of depressive symptoms and suicidal thoughts compared to controls.
105 citations
,
June 2010 in “The journal of sexual medicine” In this study, female-to-male transsexuals treated with long-acting testosterone undecanoate experienced an increase in lean mass but no change in fat mass or bone mineral density over 24 months.
209 citations
,
September 2008 in “Dermatologic Therapy” This review discusses the role of androgens in hair follicle regulation and suggests that a better understanding could enhance treatments for conditions like hirsutism and alopecia, but does not present new findings.
174 citations
,
November 2002 in “Expert Reviews in Molecular Medicine” This review discusses the genetic factors contributing to androgenetic alopecia and highlights the potential for developing more effective therapies based on recent discoveries, but reports no new clinical results.
176 citations
,
August 2000 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” In this study, cross-sex hormone therapy affected hair growth patterns differently, with estrogen reducing hair growth in male-to-female transsexuals and testosterone increasing it in female-to-male transsexuals; however, male typical hair diameters were not fully reached in the latter group after 12 months.
